Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
نویسندگان
چکیده
One of the main tasks modern complex therapy rheumatoid arthritis (RA) is to improve quality life patients. To do this, it necessary not only achieve remission or low activity, but also successfully control main, most painful, manifestations disease. Therefore, when evaluating results RA treatment, dynamics standard indices (DAS28 (Disease Activity Score 28), CDAI (Clinical Disease Index), SDAI (Simplified Index)), so-called “patient reported outcomes” (PRO) – a patient’s global assessment disease activity (PGA), pain, functional disorders and fatigue. This review examines effect one classes anti–rheumatic drugs - biological disease-modifying antirheumatic (bDMARDs) on PROs. The series randomized controlled trials are presented, in which changes PROs were studied using various tumor necrosis factor α (TNF-α) inhibitors, abatacept T-lymphocyte co-stimulation inhibitor, rituximab CD20 inhibitor interleukin (IL) 6 inhibitors. use bDMARDs combination with methotrexate (MTX) provides reduction PGA pain by 50-60%, according HAQ (Health Assessment Questionnaire) fatigue FACIT-F (Functional Chronic Illness Therapy Fatigue) 15-30%. B DMARDs monotherapy (with exception tocilizumab HAQ) does exceed MTX its Monotherapy more favorable than TNF-α An important advantage IL-6 inhibitors rapid achievement clinical effect, noted already first 2 weeks after administration drug.
منابع مشابه
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available. In this paper recommendations for the treatment of RA with synthetic and biological disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs) that also account for strategic algorithms and deal with economic a...
متن کاملBone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...
متن کاملPatient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
BACKGROUND This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. METHODS Patients were randomized 4:3:4 to MTX admini...
متن کاملCost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice.
متن کامل
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nau?no-prakti?eskaâ revmatologiâ
سال: 2022
ISSN: ['1995-4492', '1995-4484']
DOI: https://doi.org/10.47360/1995-4484-2022-427-437